Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design

Journal of Medical Economics

Volumn 16, Issue 7, 2013, Pages 859-865

  Cascione, Mark ^a   Wynn, Daniel ^b   Barbato, Luigi M ^c   Pestreich, Linda ^c   Schofield, Lesley ^c   McCague, Kevin ^c  

^a Tampa Neurology Associates   (United States)

^b Multiple Sclerosis Center ^*  (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Disease modifying therapy; Fingolimod; Multiple sclerosis; Patient reported outcomes; Quality of life; Treatment satisfaction; TSQM

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SEROLOGY; TREATMENT DURATION; TREATMENT RESPONSE;

CANADA; DRUG TOLERANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT-CENTERED CARE; PROPYLENE GLYCOLS; QUALITY OF LIFE; SPHINGOSINE; STANDARD OF CARE; TREATMENT OUTCOME; UNITED STATES;

EID: 84879769319     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.802239     Document Type: Article

References (28)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938-52
2. Pike J, Jones E, Rajagopalan K, et al. Social and economic burden of walking and mobility problems in multiple sclerosis. BMC Neurol 2012;12:94
3. Salter AR, Cutter GR, Tyry T, et al. Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. Curr Med Res Opin 2010;26:493-500
4. Dinan MA, Compton KL, Dhillon JK, et al. Use of patient-reported outcomes in randomized, double-blind, placebo-controlled clinical trials. Med Care 2011;49:415-9
5. Doward LC, McKenna SP, Meads DM, et al. The development of patient-reported outcome indices for multiple sclerosis (PRIMUS). Mult Scler 2009;15:1092-102
6. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118:622-9
7. Miller D, Rudick RA, Hutchinson M. Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life. Neurology 2010;74(3 Suppl):S24-35
8. Rudick RA, Miller DM. Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment. CNS Drugs 2008;22:827-39
9. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular inter-feron for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
10. Devonshire V, Havrdova E, Radue EW, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol 2012;11:420-8
11. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362: 387-401
12. Montalban X, Comi G, O'Connor P, et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study. Mult Scler 2011;17:1341-50
13. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod (FTY720) treatment improves the performance of daily activities compared with intramuscular interferon/J-1a: Patient-Reported Indices for Multiple Sclerosis (PRIMUS)-Activities results from a phase III study (TRANSFORMS). Presented at: American Academy of Neurology 62nd Annual Meeting; April 10-17, 2010; Toronto, Canada
14. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6
15. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004;2:12
16. KlawiterEC, Cross AH, Naismith RT. The present efficacy of multiple sclerosis therapeutics: is the new 66% just the old 33%? Neurology 2009;73:984-90
17. Uitdehaag BM, Barkhof F, Coyle PK, et al. The changing face of multiple sclerosis clinical trial populations. Curr Med Res Opin 2011;27:1529-37
18. Cunningham A, Gottberg K, von Koch L, et al. Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis. Acta Neurol Scand 2010;121:154-60
19. Milanese C, Beghi E, Giordano L, et al. A post-marketing study on immuno-modulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results. Neurol Sci 2005;26(4 Suppl):S171-3
20. Portaccio E, Zipoli V, Siracusa G, et al. Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients. Eur Neurol 2009;61:177-82
21. Reynolds MW, Stephen R, Seaman C, et al. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin 2010;26:663-74
22. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11:306-9
23. Ruggieri RM, Settipani N, Viviano L, et al. Long-term interferon-betatreatment for multiple sclerosis. Neurol Sci 2003;24:361-4
24. Wong J, Gomes T, Mamdani M, et al. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low. Can J Neurol Sci 2011;38:429-33
25. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-3
26. Moran PJ, Mohr DC. The validity of Beck Depression Inventory and Hamilton Rating Scale for Depression items in the assessment of depression among patients with multiple sclerosis. J Behav Med 2005;28:35-41
27. Ware Jr JE. SF-36 health survey update. Spine (Phila Pa 1976) 2000;25: 3130-9
28. Jeffery D, Calabresi P, Goodin D, et al. Oral fingolimod (FTY720) vs placebo in relapsing-remitting multiple sclerosis (RRMS): baseline data from a 2-year phase III trial (FREEDOMS II). Presented at: The Consortium of Multiple Sclerosis Centers Annual Meeting; June 2-5, 2010; San Antonio, TX